Germany: EIB provides funding of €40 million to ITM
11 February 2020
Funds will support ITM’s research and development strategy for cancer treatments
Financing by EU bank is provided under Investment Plan for Europe
The European Investment Bank (EIB) provides €40 million to ITM Isotopen Technologien München AG (ITM), a company dedicated to the development, production and global supply of innovative diagnostic and therapeutic radiopharmaceuticals for use in Precision Oncology. ITM will use the fresh funds for investments in research and development of a proprietary portfolio of Targeted Radionuclide Diagnostics and Therapies, addressing a range of cancers such as neuroendocrine tumours and bone metastases.
The EU bank’s loan is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe – the Juncker Plan – under which the EIB and the European Commission are working together as strategic partners and the EIB’s financing operations are boosting the competitiveness of the European economy.
EIB Vice-President, Ambroise Fayolle, who is responsible for EIB’s operations in Germany and EFSI, said: “ITM´s research and development activities are focussed on developing treatments for cancer diseases for which there are limited treatment options. Our financing will therefore support and accelerate the development and market launch of products that are expected to improve the lives of thousands of patients. In addition, the financing will sustain ITM’s long-term growth, which in turn will help strengthen Europe’s leading position in radiopharmaceutical research and development. This is exactly, why we have launched the Investment Plan for Europe.”
Paolo Gentiloni, European Commissioner for the Economy, said: “I am proud that the European Commission is supporting the ground-breaking cancer research being undertaken by ITM. These efforts could prove vital to so many people. Financing from the Investment Plan for Europe allows the European Investment Bank to finance highly innovative projects such as this, where the outcome is unknown but the potential for developing life-changing treatments is huge.”
ITM CEO Steffen Schuster added: “The Investment Plan for Europe is of great importance in advancing the economic growth of the EU. We are very honored to be part of it and grateful for the support of the EIB in our passionate mission to improve the outcome and quality of life of cancer patients by developing innovative, first-in-class radiopharmaceuticals. Targeted Radionuclide Therapy is considered a promising treatment for a large number of difficult-to-treat cancers. With the EIB’s funding we are looking forward to accelerating our theranostic research and the development of our growing Precision Oncology pipeline in indications such as neuroendocrine tumours and bone metastases and we feel well equipped to optimally meet patients’ needs.”
About ITM Isotopen Technologien München
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radionuclides and generator platforms for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors and bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information about ITM, please visit: www.itm.ag
The EIB has signed a $350 million loan agreement to support the financing of Europe’s first home-grown gigafactory for lithium-ion battery cells, Northvolt Ett, in Sweden. The financing is supported by the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe. In 2018, the EIB also supported the establishment of the demonstration line Northvolt Labs, which produced its first battery cells in late 2019, and which paved the way for Europe’s first home-grown gigafactory.
The EIB and the Instituto de Crédito Oficial (ICO) will provide €50 million to finance the innovation strategy of Dominion, a Spanish business group that develops integrated multi-technical engineering, installation, operation and maintenance solutions. The agreement, under which each entity will advance €25 million, will contribute to achieving the objectives of the Digital Agenda for Europe through investments in digitalisation in Spain, Germany and Denmark.
This has been one of the Italian government’s top priorities for at least three years. The government has decidedly sped up the process following the restrictions caused by the COVID-19 pandemic, and this has now become a key pillar to aid the country’s recovery. Digitalisation of public administrations (PAs) and their relations with the country’s citizens and businesses have become the focus of the digital innovation measures contained in the “Simplifications” Decree Law approved by the Prime Minister's Office on 7 July. It is against this backdrop that the four-year investment plan of publicly-owned company PagoPA S.p.A. is receiving strong backing from the European Union’s bank.